February 20, 2019
Alvogen launches its generic Suboxane in the US
Alvogen has launched its generic equivalent to Indivior UK LLC’s Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
February 20, 2019
ADC Therapeutics doses patients in testing ADCT-402, after encouraging safety profile and anti-tumor activity
Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
February 20, 2019
Beximco buys eight ANDAs in US from Novartis’ Sandoz
Beximco Pharmaceuticals Limited will buy from Novartis’ Sandoz a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US…
February 19, 2019
Pfizer Lilly use tanezumab to treat moderate-to-severe chronic low back pain in phase 3 study, it works
Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.
February 19, 2019
Roche to get quicker review of its anti cancer Rituxan combination, in August
Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
February 19, 2019
Basilea’s revenue grew year over year boosted by Cresemba and Zevtera
Basilea Pharmaceutica’s revenue grew of 31% for the full year, reaching CHF 133 million (€117M), the company said on Tuesday, noting it’s year-end cash position being at CHF 223 million.
February 15, 2019
Spring Pharmaceutical Group 13% revenue growth, third quarter net profit $4.5M
Jining, Shandong Province-based Spring Pharmaceutical Group, Inc. posted net income of $4.34 million, compared to $2.78 million for the same period of the prior fiscal year.
February 14, 2019
California court allows HIV drug personal injury cases against Gilead
The Superior Court of California, County of Los Angeles rejected all but one of Gilead’s arguments to dismiss the HIV/AIDS patients’ legal theories against the company’s TDF-based HIV/AIDS drug, that cause permanent damage tokidneys and bones.
February 12, 2019
Boehringer, IBM to test blockchain technology can help in clinical trials
Canadian Boehringer Ingelheim and IBM Canada want to find out how blockchain technology can help in clinical trials, the Boehringer…
February 12, 2019
ReGenTree, Ora in mutual clinical study drug to treat dry eye syndrome
ReGenTree and Ora will mutually start testing the ReGenTree’s new drug RGN-259 for the treatment of dry eye syndrome, in a clinical study named ARISE-3, based entirely on the results of a previous clinical trials, ARISE-1 and ARISE-2.